ArriVent BioPharma
AVBP
AVBP
80 hedge funds and large institutions have $757M invested in ArriVent BioPharma in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
18% more funds holding
Funds holding: 68 → 80 (+12)
7.33% more ownership
Funds ownership: 77.13% → 84.47% (+7.3%)
Holders
80
Holding in Top 10
6
Calls
–
Puts
–
Top Buyers
| 1 | +$10.7M | |
| 2 | +$8.99M | |
| 3 | +$5.43M | |
| 4 |
HLAM
Hidden Lake Asset Management
New York
|
+$4.92M |
| 5 |
Goldman Sachs
New York
|
+$3.58M |
Top Sellers
| 1 | -$9.75M | |
| 2 | -$4.37M | |
| 3 | -$2M | |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$1.18M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.11M |